You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Adjuvant endocrine treatment

Showing 1 - 25 of 6,158
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Breast Cancer Trial (Fluzoparib, Anastrozole, Letrozole)

Not yet recruiting
  • Breast Cancer
  • (no location specified)
Jun 5, 2023

Breast Tumors, Breast Cancer Trial (PACHA Program)

Not yet recruiting
  • Breast Neoplasms
  • Breast Cancer
  • PACHA Program
  • (no location specified)
Jun 6, 2023

Breast Cancer Trial in Boston, Danvers (Ribociclib, Endocrine therapy)

Recruiting
  • Breast Cancer
  • Boston, Massachusetts
  • +2 more
Jan 6, 2023

Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer Trial (Giredestrant, Fulvestrant, Abemaciclib)

Not yet recruiting
  • Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer
  • (no location specified)
Sep 26, 2023

Breast Cancer, Adherence, Medication, Side Effect Trial in New Haven (BETA-Text text messaging intervention)

Active, not recruiting
  • Breast Cancer
  • +2 more
  • BETA-Text text messaging intervention
  • New Haven, Connecticut
    Yale Cancer Center
Aug 10, 2022

Breast Cancer, Early Breast Cancer Trial (Camizestrant, Tamoxifen, Anastrozole)

Not yet recruiting
  • Breast Cancer, Early Breast Cancer
  • (no location specified)
Jul 11, 2023

Breast Cancer, Early Breast Cancer Trial (Camizestrant, Tamoxifen, Anastrozole)

Not yet recruiting
  • Breast Cancer, Early Breast Cancer
  • (no location specified)
Mar 7, 2023

Breast Cancer, Quality of Life, Self Efficacy Trial in Leuven (Co'moon (online website to support women with AET))

Recruiting
  • Breast Cancer
  • +2 more
  • Co'moon (online website to support women with AET)
  • Leuven, Vlaams-Brabant, Belgium
    UZ Leuven campus Gasthuisberg
May 18, 2022

Breast Cancer, Treatment Adherence, Quality of Life Trial in Stockholm (Digitized support)

Recruiting
  • Breast Cancer
  • +3 more
  • Digitized support
  • Stockholm, Sweden
  • +2 more
May 10, 2022

Breast Cancer, Survivorship, Treatment Compliance Trial in United States (Culturally Aware Adjuvant Endocrine Therapy (AET)

Not yet recruiting
  • Breast Cancer
  • +4 more
  • Culturally Aware Adjuvant Endocrine Therapy (AET) Non-Initiation Intervention
  • Boston, Massachusetts
  • +3 more
Jul 25, 2022

Breast Cancer, Osteopenia Trial in Valencia (bone densitometry)

Recruiting
  • Breast Cancer
  • Osteopenia
  • bone densitometry
  • Valencia, Spain
    Hospital Clínico Universitario de Valencia
Mar 9, 2023

Breast Cancer Trial in Limoges, Villejuif (Anti-aromatase inhibitor)

Not yet recruiting
  • Breast Cancer
  • Anti-aromatase inhibitor
  • Limoges, France
  • +1 more
Jul 25, 2022

Breast Cancer Trial in Washington, Baltimore (Outcomes4Me, Semi-structured interview)

Recruiting
  • Breast Cancer
  • Outcomes4Me
  • Semi-structured interview
  • Washington, District of Columbia
  • +1 more
Jan 13, 2023

Breast Cancer Trial in Beijing, Guangzhou (TQB3616 capsules, Letrozole, Anastrozole, Tamoxifen, Placebo capsules, Letrozole,

Not yet recruiting
  • Breast Cancer
  • TQB3616 capsules, Letrozole, Anastrozole, Tamoxifen
  • Placebo capsules, Letrozole, Anastrozole, Tamoxifen
  • Beijing, Beijing, China
  • +1 more
Mar 10, 2023

Breast Cancer Female Trial in Charlottesville, Richmond (tamoxifen, letrozole, anastrozole, or exemestane, Patient reported

Recruiting
  • Breast Cancer Female
  • tamoxifen, letrozole, anastrozole, or exemestane
  • Patient reported outcomes
  • Charlottesville, Virginia
  • +1 more
Mar 16, 2022

Breast Cancer Trial in Zhengzhou (Capecitabine+endocrine therapy, Placebo+endocrine therapy)

Recruiting
  • Breast Cancer
  • Capecitabine+endocrine therapy
  • Placebo+endocrine therapy
  • Zhengzhou, Henan, China
    Henan cancer hospital
Nov 19, 2022

Breast Cancer Trial (Ovarian Function Suppression + Aromatase Inhibitor, Adjuvant Chemotherapy + Ovarian Function Suppression)

Not yet recruiting
  • Breast Cancer
  • Ovarian Function Suppression + Aromatase Inhibitor
  • Adjuvant Chemotherapy + Ovarian Function Suppression
  • (no location specified)
May 19, 2023

Self-management Intervention (SM-AET), General Health Education Trial in Durham (SM-AET, general health education)

Active, not recruiting
  • Self-management Intervention (SM-AET)
  • General Health Education
  • SM-AET
  • general health education
  • Durham, North Carolina
    Duke University Medical Center
Jun 22, 2022

Breast Cancer Trial ([68Ga]Ga-NeoB, [177Lu]Lu-NeoB, Ribociclib)

Not yet recruiting
  • Breast Cancer
  • (no location specified)
May 22, 2023

HR+/HER2-breast Cancer Trial (Standard endocrine therapy plus Apatinib)

Not yet recruiting
  • HR+/HER2-breast Cancer
  • Standard endocrine therapy plus Apatinib
  • (no location specified)
Jun 2, 2023

HER2-positive Breast Cancer, Invasive Carcinoma of the Breast, Breast Cancer Trial in United States (Pertuzumab+TRASTUZUMAB,

Recruiting
  • HER2-positive Breast Cancer
  • +5 more
  • Pertuzumab+TRASTUZUMAB
  • ADJUVANT ENDOCRINE THERAPY
  • Stamford, Connecticut
  • +21 more
Dec 12, 2022

Breast Cancer, Adherence, Medication Trial in Boston (STRIDE, Medication Monitoring Control)

Completed
Has Results
  • Breast Cancer
  • Adherence, Medication
  • STRIDE
  • Medication Monitoring Control
  • Boston, Massachusetts
    Massachusetts General Hospital Cancer Center
Nov 7, 2022

Breast Cancer Trial in United States (Palbociclib, Aromatase Inhibitor)

Completed
Has Results
  • Breast Cancer
  • San Francisco, California
  • +9 more
Mar 18, 2022

Breast Cancer, Quality of Life Trial in Chapel Hill (Accelerated Partial Breast Irradiation (APBI), tamoxifen, anastrozole,

Recruiting
  • Breast Cancer
  • Quality of Life
  • Accelerated Partial Breast Irradiation (APBI)
  • tamoxifen, anastrozole, exemestane, letrozole, fulvestrant, toremifene
  • Chapel Hill, North Carolina
    University of North Carolina
Jul 22, 2022

Menstrual Cycle, PAM50, Ki67 on Treatment Decisions in HR+ and

Recruiting
  • Hormone Receptor Positive HER-2 Negative Breast Cancer
    • Tuebingen, Germany
      Department of Women's Health
    Jun 1, 2023